Numerous studies have demonstrated the safety and effectiveness of TMS in MDD/OCD/Anxiety, especially in treatment-resistant patients who have not responded to medications. Approximately 58% of treatment-resistant patients respond positively to TMS therapy.
Dr. Aimua provides psychiatric treatment for various DSM 5 psychiatric disorders using a combined approach of medication management with psychotherapy. Gene-sight Genetic Testing: A pharmacogenomic test that analyzes clinically important genetic variations that may impact how the patient metabolizes and responds to certain medications. Dr. Aimua now provides INTRANASAL KETAMINE (SPRAVATO)for treatment for depression. (See below for details)